Springer Nature
Browse
12916_2018_1233_MOESM3_ESM.pdf (171.88 kB)

Additional file 3: of Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Download (171.88 kB)
journal contribution
posted on 2019-01-09, 05:00 authored by Joaquín Gavilá, Mafalda Oliveira, Tomás Pascual, Jose Perez-Garcia, Xavier Gonzàlez, Jordi Canes, Laia Paré, Isabel Calvo, Eva Ciruelos, Montserrat Muñoz, Juan Virizuela, Isabel Ruiz, Raquel Andrés, Antonia Perelló, Jerónimo Martínez, Serafín Morales, Mercedes Marín-Aguilera, Débora Martínez, Juan Quero, Antonio Llombart-Cussac, Aleix Prat
Table S1. Overall study population and biomarker population characteristics. (PDF 171 kb)

Funding

Instituto de Salud Carlos III

History

Usage metrics

    BMC Medicine

    Categories

    Keywords

    Breast cancerPAM50HER2intrinsic subtypescardiac safetyHER2-enrichedneoadjuvant

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC